Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 214390260 approvals28 trials

KYONGBO PHARMACEUTICAL CO., LTD.

Official website

Founded in 1987, Kyongbo Pharmaceutical is an API specialist producing cephalosporin antibiotics like ceftriaxone and developing ADC conjugation technology.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1987 and listed on KOSPI in 2015, Kyongbo Pharmaceutical is a pharmaceutical company specializing in active pharmaceutical ingredients (APIs). Its API segment produces and exports cephalosporin antibiotics such as ceftriaxone and has developed proprietary ADC conjugation and payload-linker technology, while its finished-drug segment sells prescription products including Maxigesic injection, Vilda/Vildamet tablets, and the inhalation anesthetic Surgeon. In its Q4 2025 report, API revenue was KRW 133,833 million and finished-drug revenue KRW 126,485 million, for total revenue of KRW 264,104 million, and the company diversified into medical devices in 2018 and animal health in 2020.

Products & technology

  • CeftriaxoneCephalosporin antibiotic API, exported domestically and overseas
  • ADC conjugation / payload-linker technologyProprietary technology developed for entry into the ADC CDMO market
  • Maxigesic InjectionCombination analgesic injection (finished drug)
  • Vilda / Vildamet Tab.Finished drug product
  • Surgeon Inhalation AnestheticInhalation anesthetic
  • Rosuage Tab.Finished drug product
  • Kyongbo Cefpodoxime Proxetil Tab.Antibiotic (finished drug)

Regulatory approvals

data.go.kr

259 Korean MFDS drug approvals · 1994–2026 / 1 Korean MFDS device approvals · 2025

  • MFDS drugTelmilopine S Tab. 40/5mg2026-08-19
    Drug · Prescription · Approval202602406
  • MFDS drugTelmilopine S Tab. 40/2.5mg2026-08-19
    Drug · Prescription · Approval202602407
  • MFDS drugTelmilopine S Tab. 80/2.5mg2026-08-06
    Drug · Prescription · Approval202602264
  • MFDS drugTelmilopine S Tab. 80/5mg2026-08-06
    Drug · Prescription · Approval202602265
  • MFDS drugVonokhan Tablet 20mg (Vonoprazan tosylate)2026-01-09
    Drug · Prescription · Approval202600067
  • MFDS drugVonokhan10mg(Vonoprazan Tosylate)2026-01-09
    Drug · Prescription · Approval202600068
  • MFDS drugKayglito Tab. 25/5mg(Empagliflozin, Linagliptinbesylate)2025-11-21
    Drug · Prescription · Approval202503048
  • MFDS drugKayglito Tab. 10/5mg(Empagliflozin, Linagliptinbesylate)2025-11-21
    Drug · Prescription · Approval202503049
  • MFDS drugEmpazamet tab. 12.5/500mg2025-11-18
    Drug · Prescription · Approval202502977
  • MFDS drugEmpazamet tab. 12.5/850mg2025-11-18
    Drug · Prescription · Approval202502978
  • MFDS drugEmpazamet12.5/850mg2025-11-13
    Drug · Prescription · Approval202502937
  • MFDS drugEmpazamet tab. 5/1000mg2025-11-13
    Drug · Prescription · Approval202502938
Show 68 more
  • MFDS drugEmpazamet tab. 5/500mg2025-11-12
    Drug · Prescription · Approval202502920
  • MFDS drugEmpazamet tab. 5/850mg2025-11-12
    Drug · Prescription · Approval202502921
  • MFDS drugEmpaza tab. 10mg2025-11-10
    Drug · Prescription · Approval202502902
  • MFDS drugEmpaza tab. 25mg2025-11-10
    Drug · Prescription · Approval202502903
  • MFDS drugJang & Q Capsule2025-07-31
    Drug · OTC · Notification202501999
  • MFDSGlove, patient examination2025-04-25
    Product approval · Class 1수신 25-835 호
  • MFDS drugGinef Tab. 2402024-08-27
    Drug · OTC · Notification202402065
  • MFDS drugLirajenta Duo SR Tab. 2.5/1000mg2024-06-27
    Drug · Prescription · Approval202401557
  • MFDS drugLirajenta Duo SR Tab. 5/1000mg2024-06-27
    Drug · Prescription · Approval202401558
  • MFDS drugLirajenta Duo Tab. 2.5/1000mg2024-04-30
    Drug · Prescription · Approval202401040
  • MFDS drugLirajenta Duo Tab. 2.5/850mg2024-04-30
    Drug · Prescription · Approval202401041
  • MFDS drugLirajenta Duo Tab. 2.5/500mg2024-04-30
    Drug · Prescription · Approval202401042
  • MFDS drugJoinchondro 800 Tab2024-04-26
    Drug · OTC · Notification202400995
  • MFDS drugLirajenta Tab. 5mg2024-03-29
    Drug · Prescription · Approval202400690
  • MFDS drugDAPAKHANMET XR Tab. 10/500mg2023-06-21
    Drug · Prescription · Approval202301896
  • MFDS drugJANUSMET TAB. 50/850mg2023-03-13
    Drug · Prescription · Approval202300833
  • MFDS drugJANUSMET TAB. 50/500mg2023-03-13
    Drug · Prescription · Approval202300834
  • MFDS drugJANUSMET TAB. 50/1000MG2023-03-13
    Drug · Prescription · Approval202300835
  • MFDS drugJanustinmet XR Tab. 50/1000mg2023-02-17
    Drug · Prescription · Approval202300581
  • MFDS drugJanustinmet XR Tab. 50/500mg2023-02-17
    Drug · Prescription · Approval202300582
  • MFDS drugJanustinmet XR Tab. 100/1000mg2023-02-17
    Drug · Prescription · Approval202300583
  • MFDS drugJanustinDuo tab.10/100mg2023-01-30
    Drug · Prescription · Approval202300384
  • MFDS drugDAPAKHANMET XR Tab. 10/1000mg2023-01-06
    Drug · Prescription · Approval202300146
  • MFDS drugRyuma600power Tab2022-12-29
    Drug · OTC · Notification202204692
  • MFDS drugRamokhan prefilled2022-11-07
    Drug · Prescription · Approval202204015
  • MFDS drugVildamet tab 50/850mg2021-11-30
    Drug · Prescription · Approval202107713
  • MFDS drugVildamet tab 50/500mg2021-11-30
    Drug · Prescription · Approval202107714
  • MFDS drugVildamet tab 50/1000mg2021-11-30
    Drug · Prescription · Approval202107715
  • MFDS drugPlatop gel2021-10-19
    Drug · OTC · Notification202107009
  • MFDS drugVilda tab 50mg2021-09-10
    Drug · Prescription · Approval202106501
  • MFDS drugMaxigesic Inj.2021-08-30
    Drug · Prescription · Approval202106243
  • MFDS drugJolerone injection 5 mg/100mL(zoledronic acid monohydrate)2021-08-27
    Drug · Prescription · Approval202106203
  • MFDS drugJanustin tab. 50mg2021-03-29
    Drug · Prescription · Approval202102719
  • MFDS drugJanustin tab. 25mg2021-03-29
    Drug · Prescription · Approval202102720
  • MFDS drugJanustin tab. 100mg2021-03-29
    Drug · Prescription · Approval202102721
  • MFDS drugDAPAKHAN Tab. 10mg2021-02-08
    Drug · Prescription · Approval202101181
  • MFDS drugKyongbo Cefprozil dry syrup2021-01-19
    Drug · Prescription · Notification202100550
  • MFDS drugAtoeze tab 10/10mg2021-01-08
    Drug · Prescription · Approval202100233
  • MFDS drugAtoeze tab 10/20mg2021-01-08
    Drug · Prescription · Approval202100234
  • MFDS drugAtoeze tab 10/40mgRevoked2021-01-08
    Drug · Prescription · Approval202100235
  • MFDS drugCANDEROVA Tab. 5/8mgRevoked2020-12-11
    Drug · Prescription · Approval202008711
  • MFDS drugCANDEROVA Tab. 5/16mgRevoked2020-12-11
    Drug · Prescription · Approval202008712
  • MFDS drugCANDEROVA Tab. 20/32mgRevoked2020-12-11
    Drug · Prescription · Approval202008713
  • MFDS drugCANDEROVA Tab. 10/8mgRevoked2020-12-11
    Drug · Prescription · Approval202008714
  • MFDS drugCANDEROVA Tab. 10/16mgRevoked2020-12-11
    Drug · Prescription · Approval202008715
  • MFDS drugDexpanten tab 100mgRevoked2020-11-26
    Drug · OTC · Notification202008259
  • MFDS drugPakis Tab.Revoked2020-09-21
    Drug · Prescription · Approval202006508
  • MFDS drugBromel Tab. 45mg2020-09-03
    Drug · OTC · Notification202006143
  • MFDS drugAldakill Tab.Revoked2020-07-27
    Drug · OTC · Notification202005446
  • MFDS drugClasone CreamRevoked2020-06-29
    Drug · OTC · Notification202004716
  • MFDS drugBenazole Cream2020-05-18
    Drug · OTC · Notification202003611
  • MFDS drugTime-R SR Cap. 0.4mg2020-04-22
    Drug · Prescription · Approval202002885
  • MFDS drugPencivir CreamRevoked2020-04-05
    Drug · Prescription · Notification202002379
  • MFDS drugFamoton Tab. 20mg2020-03-18
    Drug · Prescription · Approval202001905
  • MFDS drugBromel Enteric Coated Tab.Revoked2020-02-17
    Drug · OTC · Notification202001043
  • MFDS drugUbican Cap.2020-02-04
    Drug · Prescription · Approval202000618
  • MFDS drugApixol Tab. 5mg2020-01-31
    Drug · Prescription · Approval202000523
  • MFDS drugApixol Tab. 2.5mg2020-01-31
    Drug · Prescription · Approval202000524
  • MFDS drugWemebutine Tab. 150mg2019-11-20
    Drug · OTC · Notification201908017
  • MFDS drugGinef Tab. 80mg2019-11-18
    Drug · OTC · Notification201907970
  • MFDS drugGinef Tab.2019-11-18
    Drug · OTC · Notification201907971
  • MFDS drugCandetan Tab. 16mg2019-11-14
    Drug · Prescription · Approval201907938
  • MFDS drugCandetan Tab. 8mg2019-11-14
    Drug · Prescription · Approval201907939
  • MFDS drugGel Cover Double Action SuspensionRevoked2019-11-12
    Drug · OTC · Notification201907880
  • MFDS drugAlgit Sol.Revoked2019-10-21
    Drug · Prescription · Notification201907371
  • MFDS drugK-Met SR Tab2019-09-26
    Drug · Prescription · Approval201906866
  • MFDS drugNovaltan Tab. 10/160mg2019-09-25
    Drug · Prescription · Approval201906827
  • MFDS drugTazopicin Inj. 2.25g2019-08-30
    Drug · Prescription · Notification201906207

Showing the 80 most recent of 260 records.

Clinical trials

data.go.kr

28 MFDS clinical trial authorisations · 2012–2026 (Phase 1 15 · Bioequivalence 13)

  • BioequivalenceKBP-RZ-262026-03-05

    2 trial sites

  • Phase 1KBP-25-01-A2025-10-20

    1 trial site

  • Phase 1보노칸정20밀리그램2024-09-10

    1 trial site

  • Phase 1K08-23-02-B2024-06-04

    1 trial site

  • Phase 1K08-23-02-B2024-05-02

    1 trial site

  • Phase 1K08-23-02-A2024-03-14

    1 trial site

  • Phase 1K08-23-02-A2024-02-05

    1 trial site

  • Phase 1K08-22-192023-09-21

    1 trial site

  • Phase 1K08-22-182023-09-21

    1 trial site

  • Phase 1경보리나글립틴메트포르민서방정(K08-22-06)2022-12-20

    2 trial sites

  • Phase 1경보리나글립틴메트포르민서방정(K08-22-06)2022-12-19

    2 trial sites

  • Phase 1경보리나글립틴메트포르민속방정(K08-22-07)2022-10-26

    2 trial sites

Show 16 more
  • Phase 1경보리나글립틴정2022-10-14

    2 trial sites

  • Bioequivalence노발탄정10/160밀리그램2021-08-27

    2 trial sites

  • Bioequivalence에이스틴정20밀리그램(아토르바스타틴칼슘수화물)2021-07-06

    2 trial sites

  • Bioequivalence수바스틴정(로수바스타틴칼슘)2021-07-06

    2 trial sites

  • Phase 1빌다메트정50/1000밀리그램 (KBP-702)2020-03-12

    2 trial sites

  • Phase 1빌다정50밀리그램 (KBP-701)2020-03-12

    2 trial sites

  • Bioequivalence세토렌세립(세프디토렌피복실)2019-03-06

    2 trial sites

  • Bioequivalence경보세프디토렌정(세프디토렌피복실)100밀리그램2018-10-30

    2 trial sites

  • Phase 1KB_RASA2018-04-23

    1 trial site

  • Bioequivalence경보세파클러캡슐2017-05-22

    2 trial sites

  • Bioequivalence경보오셀타미비르현탁용분말6mg/mL(오셀타미비르인산염)2017-01-11

    2 trial sites

  • Bioequivalence경보세푸록심악세틸정250밀리그램2016-02-03

    2 trial sites

  • Bioequivalence경보 타다라필정 20mg2014-05-20

    2 trial sites

  • Bioequivalence경보세파드록실수화물캡슐500밀리그램2013-11-27

    2 trial sites

  • Bioequivalence경보세푸록심악세틸정2012-08-13
  • Bioequivalence경보세프프로질정(세프프로질수화물)2012-04-20

R&D and key agreements

Source: DART corporate disclosure

ADC 항암제 접합기술 및 Payload-Linker 기술 개발 · 항암 · Preparing entry into the global ADC CDMO market

Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Billions Co.,Ltd.1 shared

Founded in 1973, KOSDAQ-listed in 2001, Billions makes medical rubber products like condoms and runs an entertainment business.

DAIHAN SCIENTIFIC CO., Ltd1 shared

KOSDAQ-listed lab equipment company manufacturing and distributing ultra-low temperature freezers, centrifuges, and autoclaves.

SEWOONMEDICAL CO,. LTD.1 shared

Founded in 1982 and KOSDAQ-listed in 2008, Sewoon Medical manufactures medical aspirators and catheters/tubes.

SHINHUNG CO.,LTD1 shared

Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition